linezolid (Zyvox)

DRUG3 trials

Sponsors

Pfizer

Conditions

Methicillin Resistant Staphylococcus Aureus (MRSA)PneumoniaStaphylococcal Infections

Phase 4

Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

CompletedNCT00084266

PfizerMethicillin Resistant Staphylococcus Aureus (MRSA)

Start: 2004-10-31End: 2010-03-31Updated: 2012-02-01

Unknown Phase

Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)

CompletedNCT00666276

PfizerStaphylococcal Infections

Start: 2007-02-28End: 2011-04-30Updated: 2012-07-02

Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia

CompletedNCT01819935

PfizerPneumonia

Start: 2012-12-31End: 2013-01-31Updated: 2014-01-30

Related Papers

The effect of diabetes mellitus on outcomes of patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: data from a prospective double-blind clinical trial comparing treatment with linezolid versus vancomycin

BMC Infectious Diseases2016-09-0622 citations

Predictors of Clinical Success in the Treatment of Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Nosocomial Pneumonia (NP)

PLoS ONE2015-07-218 citations

Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.

2013-09-0315 citations